Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that it has officially initiated its ISO 15189 accreditation program with the Standards Council of Canada (SCC) for its medical laboratory in Quebec City. The accreditation process officially commenced on December 19, 2025. BioMark has engaged the Standards
Technology, Biotechnology, Healthcare and Hospitals
2025-12-23 8:30 AM EST | BioMark Diagnostics, Inc.
Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has received aggregate gross proceeds of approximately CAD$590,000 through the exercise of previously issued common share purchase warrants and the closing of a corporate loan. The Company reports that holders of previously issued warrants exercised an aggregate of 4,103,023 warrants for
Technology, Biotechnology, Health
2025-12-22 12:00 PM EST | Restart Life Sciences Corp.
Entheon Announces Letter of Intent with Nutravisor Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a binding Letter of Intent (the "LOI") dated December 18, 2025, with Nutravisor Inc. ("Nutravisor") whereby Entheon will acquire all of the issued and outstanding common shares of Nutravisor (the "Proposed Transaction"). Upon completion of the Proposed T
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2025-12-22 9:30 AM EST | Entheon Biomedical Corp.
Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart" or the "Company") is pleased to announce that it has signed a binding letter of intent dated December 21st, 2025 (the "LOI"), which sets out the proposed terms by which the Company would acquire 100% of the shares of Holy Crap Foods Inc. ("Holy Crap"), from Happy Belly Food Group Inc. (CSE: HBFG) (the "Ac
Technology, Biotechnology, Health
2025-12-22 8:00 AM EST | Restart Life Sciences Corp.
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighte
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-22 7:00 AM EST | Cannabis Bioscience International Holdings
Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that the non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering") previously announced on October 14, 2025 has been updated. The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share
2025-12-19 5:05 PM EST | Sharp Therapeutics Corp.
Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM) Minimal Residual Disease (MRD) clinical trial in collaboration with the University of Athens. This retrospective study is a key component of Telo's expanding, multi-center MRD validation program and is designed
2025-12-18 4:05 PM EST | Telo Genomics Corp.
Maxwell Biosciences Subsidiary Havih Announces Partnership with the Government of Andhra Pradesh
Austin, Texas--(Newsfile Corp. - December 18, 2025) - Maxwell Biosciences subsidiary, Havih Envirosciences, an Indian citizen-owned and operated life sciences company, announced a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities in the state. The collaboration was formalized through an agreement with the Andhra Pradesh Centre for Advanced Research on Livestock Limited (APCARL) on November 21, 2025.
Biotechnology, Pharmaceuticals
2025-12-18 9:00 AM EST | Maxwell Biosciences, Inc.
Restart Life Closes Over-Subscribed Second Tranche Financing
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025 and December 5, 2025, the Company has closed the over-subscribed second tranche of its non-brokered private placement for total gross proceeds of CDN$630,000 (the "Placement"). As announced on November 12, 2025, the company intended to raise a total of up t
Technology, Biotechnology, Health
2025-12-18 8:00 AM EST | Restart Life Sciences Corp.
Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has achieved yet another milestone by reaching the midway point of the study's full enrollment target. Despite holiday scheduling and year-end operating room
Biotechnology, Healthcare and Hospitals
2025-12-18 8:00 AM EST | Envoy Medical, Inc.
BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence
Biotechnology, Pharmaceuticals, Health
2025-12-18 7:30 AM EST | BioHarvest Sciences Inc.
Optimi Health Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-18 7:00 AM EST | Optimi Health Corp.
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin. InStatin, a biotechnology company developing inhaled statin therapies for respiratory diseases, today reported significant progress from June 2024 through December 2025, despite a
Technology, Biotechnology, Health
2025-12-18 7:00 AM EST | Therma Bright Inc.
MustGrow: CEO Letter to Shareholders 2025
Saskatoon, Saskatchewan--(Newsfile Corp. - December 18, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to issue a letter to shareholders from Corey Giasson, MustGrow's President and CEO. Dear MustGrow shareholders and stakeholders, I hope everyone is well and ready to enjoy a peaceful and festive holiday season with family and friends. I am writing this letter to share our excitement in what
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-12-18 7:00 AM EST | MustGrow Biologics Corp.
InMed Announces Results of 2025 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the "Meeting"), the matters put forward before shareholders for consideration and ap
Biotechnology, Pharmaceuticals
2025-12-17 8:00 PM EST | InMed Pharmaceuticals
TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
Highlights: Manufacturing site in Florida expands TempraMed's U.S. production footprint Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers Shortens delivery timelines and improves service for customers in the United States where majority of devices have been sold to date Reduces COGS through localized production, improved logistics
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-17 5:00 PM EST | TempraMed Technologies Ltd
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has filed a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accor
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-17 4:19 PM EST | NervGen Pharma Corp.
Restart Life Announces Food Technology and Research Studies
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update regarding its previously disclosed intention to fund food-related research initiatives (the "Research Initiatives") in support of its expanding portfolio of consumer health and wellness products. The Company is now in a position to allocate capital toward the Resear
Technology, Biotechnology, Health
2025-12-17 12:44 PM EST | Restart Life Sciences Corp.
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is very pleased to announce positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S"
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-17 8:00 AM EST | BioVaxys Technology Corp.